SCHEMBL23657474

SCHEMBL23657474

c1ccc(-c2nnc(-c3csc(-c4cccnc4)n3)o2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.69
KDM4E B2RXH2 4/20 0.69
ALDH1A1 P00352 2/20 0.69
CYP19A1 P11511 8/20 0.65
NPC1 O15118 3/20 0.65
AXL P30530 1/20 0.64
PBRM1 Q86U86 1/20 0.64
MKNK1 Q9BUB5 1/20 0.64
MKNK2 Q9HBH9 1/20 0.64
HPGDS O60760 1/20 0.60
HSD17B10 Q99714 2/20 0.58
MAPT P10636 2/20 0.58
HPGD P15428 2/20 0.58
MEN1 O00255 1/20 0.58
LMNA P02545 1/20 0.58
ALOX15 P16050 1/20 0.58
KMT2A Q03164 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TDP1 Q9NUW8 2/20 0.56
MAPK1 P28482 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7495850 0.82 RAB9A (1.00) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL4881342 0.82 KDM4E (0.66) RAB9AKDM4EALDH1A1CYP19A1NPC1
Hydrochloric Acid SCHEMBL11452940 0.81 RAB9A (0.97) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL3613262 0.81 RAB9A (0.56) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL11460926 0.80 RAB9A (0.94) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL19051411 0.79 CYP19A1 (1.00) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL30128572 0.79 CYP19A1 (1.00) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL6196239 0.79 CYP19A1 (1.00) RAB9AKDM4EALDH1A1CYP19A1NPC1
SCHEMBL13197417 0.79 NPC1 (0.74) RAB9AKDM4EALDH1A1NPC1HSD17B10
SCHEMBL6649362 0.76 CYP19A1 (0.87) RAB9AKDM4EALDH1A1CYP19A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210220408-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE EDIGENE BIOTECHNOLOGY, INC. (CN) 2021-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210220408-A1 ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE AHR, ARNT, ARSA RAB9A 4056/4885KDM4E 1784/4885ALDH1A1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.